Kyowa Kirin Co.,Ltd. Logo

Kyowa Kirin Co.,Ltd.

Develops antibody medicines for oncology, nephrology, immunology, and allergy.

4151 | T

Overview

Corporate Details

ISIN(s):
JP3256000005
LEI:
Country:
Japan
Address:
千代田区大手町一丁目9番2号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kyowa Kirin is a global specialty pharmaceutical company dedicated to addressing unmet medical needs through innovative drug discovery. The company engages in the research, development, manufacturing, and commercialization of pharmaceuticals and biotechnology products. Focusing on core therapeutic areas such as nephrology, oncology, immunology, and allergy, Kyowa Kirin leverages its advanced antibody technologies to create novel medicines. Guided by its mission of "Commitment to Life," the organization strives to deliver life-changing value to patients, their families, and medical professionals worldwide by developing and marketing innovative prescription drugs that contribute to global health and well-being.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-07-31 08:30
Interim Report
半期報告書-第103期(2025/01/01-2025/12/31)
Japanese 991.7 KB
2025-07-31 08:30
Report Publication Announcement
確認書
Japanese 8.1 KB
2025-07-11 09:30
Regulatory News Service
臨時報告書
Japanese 21.2 KB
2025-03-21 06:47
Registration Form
訂正有価証券届出書(参照方式)
Japanese 46.5 KB
2025-03-21 06:41
Post-Annual General Meeting Information
臨時報告書
Japanese 26.8 KB
2025-03-19 07:51
Registration Form
有価証券届出書(参照方式)
Japanese 56.3 KB
2025-03-11 07:31
Annual Report
有価証券報告書-第102期(2024/01/01-2024/12/31)
Japanese 4.0 MB
2025-03-11 07:31
Governance Information
内部統制報告書-第102期(2024/01/01-2024/12/31)
Japanese 22.5 KB
2025-03-11 07:31
Registration Form
確認書
Japanese 8.2 KB
2024-11-14 07:30
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 26.6 KB
2024-10-31 07:30
Board/Management Information
臨時報告書
Japanese 26.1 KB
2024-10-11 08:30
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.9 KB
2024-09-12 08:32
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 28.2 KB
2024-08-09 08:30
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 26.1 KB
2024-08-01 08:31
Interim Report
半期報告書-第102期(2024/01/01-2024/12/31)
Japanese 916.7 KB

Automate Your Workflow. Get a real-time feed of all Kyowa Kirin Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kyowa Kirin Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kyowa Kirin Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Scilex Holding Co Logo
Develops and commercializes non-opioid products for acute and chronic pain management.
United States of America
SCLX
Scinai Immunotherapeutics Ltd. Logo
Dual-model biopharma: developing NanoAbs for I&I and offering CDMO services.
United States of America
SCNI
SciSparc Ltd. Logo
Developing cannabinoid-based therapies for central nervous system (CNS) disorders.
United States of America
SPRC
Develops high-purity stem cell therapies for incurable immunological and inflammatory diseases.
South Korea
298060
scPharmaceuticals Inc. Logo
Commercializes subcutaneous drug-device therapies for at-home cardiorenal care.
United States of America
SCPH
SCYNEXIS INC Logo
Developing novel anti-fungal therapies for difficult-to-treat, drug-resistant infections.
United States of America
SCYX
Seach Medical Group Ltd. Logo
Researches, cultivates, and produces certified medical cannabis oils and flowers for global markets.
Israel
SEMG
SEEGENE, INC. Logo
Develops multiplex qPCR diagnostic assays and automated systems for labs and healthcare worldwide.
South Korea
096530
SEIKAGAKU CORPORATION Logo
A research pharma company using glycoscience to develop drugs for orthopedic & ophthalmic diseases.
Japan
4548
SELLAS Life Sciences Group, Inc. Logo
Late-stage biopharma developing novel immunotherapies for a broad range of cancers.
United States of America
SLS

Talk to a Data Expert

Have a question? We'll get back to you promptly.